New Two-in-One diabetes drug put to the test

NCT ID NCT06403761

Summary

This study tested a new investigational drug called CagriSema, which combines two medicines, to see how it helps the body use insulin in people with type 2 diabetes. 158 participants, who were already taking metformin, received either CagriSema, one of its components, or a placebo for about 42 weeks. The main goal was to measure changes in how well the body responds to insulin and how the pancreas functions.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Profil Institut für Stoffwechselforschung GmbH

    Neuss, 41460, Germany

Conditions

Explore the condition pages connected to this study.